Newsletter | July 13, 2021

07.13.21 -- COVID-19 Gets Quantum Treatment For Drug Discovery

 
Sponsor
Industry Insights
Successful Techniques For Progressing Biotherapeutic Candidates From Late Discovery To The Clinic

The reality is that many initially promising biotherapeutic candidates never make it to commercialization. It is estimated that only 1 in 1000 preclinical candidates reach the commercial market. Why does this happen? There are many that fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. In our latest white paper, we help you to prepare for a successful transition to bring your drug candidate from discovery to the clinic.

Are You Prepared To Move A Bioconjugate Candidate From Clinic To Market?

Antibody drug conjugates (ADCs) have become a groundbreaking tool in the industry’s fight against cancer, but despite the potential of ADCs and other bioconjugates, they present a wide range of challenges for drug manufacturers trying to navigate their way to commercial success.

Explore Protein Function Using Surface Plasmon Resonance (SPR)

We’ve collected a few examples of how an academic research group used Biacore™ X100 SPR system in their research to investigate protein-RNA, protein-protein interactions, and how researchers have used SPR to measure antibody specificity. Download the white paper A year of interaction with Biacore™ X100.

What Can You Do To Overcome Immunogenicity And Immunotoxicity Assessment Challenges?

On July 14, Noel Smith, Ph.D., Head of Immunology at Lonza Biologics, will present a webinar about the challenges of assessing immunogenicity and immunotoxicity when moving a drug candidate to FIH studies and the impact that has on drug development timelines and success.

Sponsor
Most Popular News
Solutions
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.